RUTGERS, THE STATE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Rutgers COVID-19 Cohort Study

Active, not recruiting

Conditions: SARS-CoV-2
Coronavirus

Interventions: Other: Non-Interventional

First Posted Date: 2020-04-07

Last Posted Date: 2023-06-01

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 829

Registration Number: NCT04336215

Locations: 🇺🇸
University Hospital, Newark, New Jersey, United States
🇺🇸
Clinical Research Unit Rutgers New Jersey Medical School, Newark, New Jersey, United States
🇺🇸
RUCDR Infinite Biologics, Piscataway, New Jersey, United States

and more 4 locations

Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19

Phase 2

Terminated

Conditions: SARS-CoV-2
COVID-19

Interventions: Combination Product: Hydroxychloroquine Sulfate + Azithromycin
Drug: Hydroxychloroquine Sulfate

First Posted Date: 2020-04-07

Last Posted Date: 2023-02-28

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 75

Registration Number: NCT04336332

Locations: 🇺🇸
Saint Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸
Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 2 locations

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Colon Carcinoma
Metastatic Colorectal Carcinoma
Refractory Colorectal Carcinoma
Stage IV Colon Cancer AJCC v7
Stage IVA Colon Cancer AJCC v7
Stage IVB Colon Cancer AJCC v7

Interventions: Drug: Oxaliplatin
Drug: Trifluridine and Tipiracil Hydrochloride

First Posted Date: 2020-03-04

Last Posted Date: 2024-11-18

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 50

Registration Number: NCT04294264

Locations: 🇺🇸
Saint Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸
RWJBarnabas Health - Monmouth Medical Center Southern Campus, Lakewood, New Jersey, United States
🇺🇸
Trinitas Hospital and Comprehensive Cancer Center, Elizabeth, New Jersey, United States

and more 3 locations

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2

Withdrawn

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory Burkitt Lymphoma
High Grade B-Cell Lymphoma, Not Otherwise Specified
Recurrent Burkitt Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Interventions: Drug: Bortezomib
Biological: Rituximab
Drug: Venetoclax

First Posted Date: 2020-02-26

Last Posted Date: 2020-06-16

Lead Sponsor: Rutgers, The State University of New Jersey

Registration Number: NCT04285268

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

Phase 2

Recruiting

Conditions: Stage II Prostate Cancer AJCC v8
Stage IIA Prostate Cancer AJCC v8
Stage IIC Prostate Cancer AJCC v8
Stage I Prostate Cancer AJCC v8
Stage IIB Prostate Cancer AJCC v8

Interventions: Radiation: High-Dose Rate Brachytherapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Stereotactic Ablative Radiotherapy

First Posted Date: 2020-02-05

Last Posted Date: 2023-11-13

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 10

Registration Number: NCT04253483

Locations: 🇺🇸
RWJBarnabas Health - Saint Barnabas Medical Center, Livingston, Livingston, New Jersey, United States
🇺🇸
Rutgers New Jersey Medical School, Newark, New Jersey, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Yoga for Anxiety in Adults

Not Applicable

Completed

Conditions: Parkinson Disease
Anxiety

Interventions: Other: Tele-yoga

First Posted Date: 2020-01-27

Last Posted Date: 2022-09-21

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 16

Registration Number: NCT04240899

Locations: 🇺🇸
Rutgers University, Newark, New Jersey, United States

Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders

Recruiting

Conditions: Essential Tremor
Movement Disorders
Huntington Disease
Spinocerebellar Ataxias
Parkinson Disease
Dystonia, Primary

First Posted Date: 2020-01-18

Last Posted Date: 2022-09-21

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 210

Registration Number: NCT04231487

Locations: 🇺🇸
Rutgers University, Newark, New Jersey, United States

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Early Phase 1

Recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Loratadine
Other: Placebo
Other: Questionnaire Administration

First Posted Date: 2019-12-26

Last Posted Date: 2023-08-07

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 70

Registration Number: NCT04211259

Locations: 🇺🇸
RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Brunswick, New Jersey, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Development and Testing of a Mobile Health Application for Management of Gestational Diabetes

Not Applicable

Recruiting

Conditions: Diabetes, Gestational
Telemedicine

Interventions: Behavioral: Develop a mobile app that supports self- management and treatment for Nepalese GDM patients

First Posted Date: 2019-12-13

Last Posted Date: 2023-12-08

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 220

Registration Number: NCT04198857

Locations: 🇳🇵
Dhulikhel Hospital, Kathmandu University Hospital, Dhulikhel, Kavrepalanchok, Nepal

Sugar-Sweetened Beverage Portion Limit Study

Not Applicable

Completed

Conditions: Health Policy

Interventions: Behavioral: Sweetened beverage portion size limit

First Posted Date: 2019-12-12

Last Posted Date: 2024-02-07

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 359

Registration Number: NCT04197063

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy